title: Drug-drug interaction between voriconazole and oral hypoglycemic agents in diabetic rats.
abstract: OBJECTIVE
  The objective was to study the of drug-drug interaction between voriconazole and oral hypoglycemic agents in normal and alloxan induced diabetic rats.
  
  
  METHODS
  The study was designed in two phases. In the first phase, influence of glibenclamide (0.45 mg/kg, p.o.) and pioglitazone (2.7 mg/kg, p.o. once daily) on blood glucose levels in normoglycemic rats was studied and then influence of voriconazole (18 mg/kg, p.o. twice daily.) pre-treatment on the hypoglycemic activity studied. Simultaneously the influence of voriconazole treatment for seven consecutive days (per se effect) on blood glucose levels was also studied in normoglycemic rats. In the second phase of the study alloxan-induced diabetic rats were used to find out the influence of voriconazole pre-treatment on glibenclamide and pioglitazone induced hypoglycemic effect in pathophysiological condition. Blood samples were collected from retro orbital plexus at regular intervals of 0.0, 0.5, 1.0, 2.0, 4.0, 8.0, 12.0, 18.0 and 24.0 h after drug treatment. All the blood samples were analyzed for plasma glucose by glucose oxidase peroxidase method (GOD/POD).
  
  
  RESULTS
  The therapeutic dose of voriconazole potentiates the hypoglycemic activity of glibenclamide and pioglitazone both in normoglycemic and diabetic rats respectively.
  
  
  CONCLUSIONS
  The results indicate that the dose of oral hypoglycemic agents needs to be adjusted if co-administered with voriconazole.
authors.affiliation: Department of Pharmacology, School of Pharmacy, Anurag Group of Institutions, Venkatapur, Ghatkesar, Hyderabad, Andhra Pradesh, India.
authors.forename: Boyina Hemanth
authors.initials: BH
authors.lastname: Kumar
authors.forename: Bheemachari
authors.initials: B
authors.lastname: Joshi
authors.forename: Jayasingh Chellammal Hanish
authors.initials: JC
authors.lastname: Singh
authors.forename: Prakash V
authors.initials: PV
authors.lastname: Diwan
mesh_terms: D058888:14-alpha Demethylase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D001786:Blood Glucose / Q000187:drug effects; D003921:Diabetes Mellitus, Experimental; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D005260:Female; D005905:Glyburide / Q000008:administration & dosage / Q000494:pharmacology*; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D000077205:Pioglitazone; D011743:Pyrimidines / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D045162:Thiazolidinediones / Q000008:administration & dosage / Q000494:pharmacology*; D014230:Triazoles / Q000008:administration & dosage / Q000494:pharmacology*; D065819:Voriconazole
chemical_list: D058888:14-alpha Demethylase Inhibitors; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D011743:Pyrimidines; D045162:Thiazolidinediones; D014230:Triazoles; D065819:Voriconazole; D005905:Glyburide; D000077205:Pioglitazone
keywords: Drug-drug interaction; glibenclamide; hypoglycemic; pioglitazone; voriconazole